US Patent

US11752092 — Methods for the preparation of injectable depot compositions

Method of Use · Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2031-05-31 · 5y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for preparing injectable depot compositions that can release therapeutic levels of a drug, such as Risperdal, for at least 14 days.

USPTO Abstract

Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.

Drugs covered by this patent

Risperdal (risperidone) · Johnson & Johnson (Janssen)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3941`	—	Risperdal
`U-3941`	—	Risperdal

Patent Metadata

Patent number: US11752092
Jurisdiction: US
Classification: Method of Use
Expires: 2031-05-31
Drug substance claim: No
Drug product claim: No
Assignee: Laboratorios Farmaceuticos Rovi SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.